MediBeacon key facts
as of Oct 2026- Developer of fluorescent tracer-agent-based systems designed to help provide a vital and actionable measurement of organ function.
- MediBeacon is valued at approximately $300.0M as of Oct 2026 (last reported valuation).
- It has raised $110.6M across 10 recorded rounds; the latest was Early Stage VC ($16.1M) in Aug 2023.
- Notable investors include Gates Foundation, Jump Capital, BioGenerator Ventures, Missouri Technology Corporation, NEXT Mannheim — 16 tracked in total.
- MediBeacon has filed 10 Form Ds with the SEC since 2015, most recently Jan 2025 ($16.1M sold to 38 investors).
- Status: Privately Held (backing).
MediBeacon's last reported valuation, Sep 2019. Nothing priced has surfaced since.
- ·The complete investor list: 16 names
- ·Watch MediBeacon: the Monday email on marks, rounds and moves
MediBeacon funding rounds
10 roundsWho backs MediBeacon
16+MediBeacon valuation
MediBeacon's last reported valuation was $300 million in Sep 2019. No priced round, secondary trade or fund mark has surfaced since.
How much has MediBeacon raised?
MediBeacon has raised $111 million across 10 recorded rounds since 2012. The largest was an $8.1 million early-stage round in Jan 2022; the most recent was a $16.1 million early-stage round in Aug 2023.
MediBeacon has filed 10 Form Ds with the SEC since 2015, most recently in Jan 2025 ($16.1 million sold to 38 investors).
MediBeacon investors
16 investors are on record for MediBeacon, including Gates Foundation, Jump Capital, BioGenerator Ventures and Missouri Technology Corporation. The early-stage round in Aug 2023 drew 38 investors.
About MediBeacon
Developer of fluorescent tracer-agent-based systems designed to help provide a vital and actionable measurement of organ function. The company's monitoring system uses an optical skin sensor combined with a proprietary agent that glows in the presence of light, enabling intensive care units and hospitals to continuously monitor patients' kidney and other vital organ functions in real-time to improve patient outcomes in the ICU and the operating suite, alongside achieving optimal dosing strategies.
- Sector
- Healthcare
- HQ
- Saint Louis, MO, United States
- Founded
- 2011
- Employees
- 29
- Website
- medibeacon.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.